Laberon (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, altering gene expression to suppress inflammation, reduce mucus production, and decrease airway swelling, thereby improving airflow and symptom control.

The prescribed dose of Laberon is determined by the treating physician based on the severity of the disease, patient response, and clinical guidelines. Patients should follow the specific inhalation instructions provided by their healthcare professional.

Safety data for Laberon in pregnancy and lactation are limited. The decision to use it should be made by a qualified healthcare provider after weighing the potential benefits against any possible risks to the mother and infant.

To order Laberon, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Laberon combines an inhaled corticosteroid with a long‑acting β2‑agonist, offering both anti‑inflammatory and bronchodilator effects in a single device. This dual action can improve adherence compared with separate inhalers, while providing comparable efficacy to other combination products such as budesonide/formoterol or fluticasone/salmeterol.

Laberon should be stored at room temperature, below 25 °C, in its original packaging. Keep the inhaler away from excessive heat, moisture and direct sunlight to maintain product stability and performance.

Laberon is delivered via an inhalation aerosol (metered‑dose inhaler). The patient inhales a prescribed number of puffs, typically once or twice daily, using a slow, deep breath followed by a breath‑hold to ensure optimal drug deposition in the lungs.

Serious risks include paradoxical bronchospasm, adrenal suppression with high systemic corticosteroid exposure, severe allergic reactions (anaphylaxis), and rare cardiac arrhythmias. Patients should be monitored for these events, especially during the initial treatment period.

Laberon is contraindicated in patients with known hypersensitivity to beclometasone, formoterol, or any component of the inhaler. It should also be avoided in individuals with untreated acute asthma attacks, severe cardiovascular disorders, or those taking non‑selective β‑blockers.